HeartBeam opened at $0.41, in line with its previous close of $0.41. In the last trading session, the stock traded between $0.40 and $0.42. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in HeartBeam is now worth
$ 8.72
Resulting in a loss of
$ 91.28 (91.28%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.00 (-0.49%)
Day High
$0.42
Day Low
$0.40
Day Open
$0.41
Prev Close
$0.41
Volume
3,79,288
1W Return
-3.76%
1M Return
-3.31%
3M Return
-29.24%
6M Return
-53.88%
1Y Return
-76.22%
Market Cap ($ Mn)
23
PE Ratio
-
PB Ratio
3.22
PEG Ratio
-
ROE
-641.72%
ROCE
-645.44%
EPS (TTM)
$-0.09
1 Week
-3.76%
1 Month
-3.31%
3 Months
-29.24%
6 Months
-53.88%
9 Months
-69.02%
HeartBeam Q3FY26 Results: Conference call scheduled for Nov 12
HeartBeam to host Q3FY26 earnings call on November 12, 2026. Management to update on ALIGN-ACS pilot study results. Discussion includes milestones for Heart Attack Detection program. Press release with financial results issued prior to call.
9 days agoHeartBeam completes enrollment ahead of schedule in 486-patient study
HeartBeam completed enrollment of 486 patients in HEADSTART-ACS study ahead of schedule. Study conducted at National Cardiovascular Center Harapan Kita in Jakarta, Indonesia. Total clinical experience exceeds 600 patients including 132 from ALIGN-ACS pilot. Results expected at a cardiology conference in 2027; U.S. pivotal study planned for Q1 2027.
22 days agoHeartBeam joins EU-funded EXIT-CVD research project on cardiac care
HeartBeam joins the EU-funded EXIT-CVD research consortium led by UMCG and Royal Philips. HeartBeam leads the HEART-CHECK study, one of 22 studies in the project. Study evaluates at-home 3D ECG for early detection of recurrent cardiac events in post-ACS patients. Partners include Medtronic and GE HealthCare alongside HeartBeam.
28 days agoHeartBeam secures FDA Breakthrough designation for at-home cardiac tool
HeartBeam received FDA Breakthrough Device Designation for its at-home cardiac assessment tool. Regulatory review completed in under 30 days, half the standard statutory timeframe. Designation facilitates prioritized interactions and potential expedited Medicare reimbursement. Clinical validation includes data from a 134-patient pilot study and AHA presentations. Shares rose 62.43% to 71 cents following the announcement.
1mo agoHeartBeam pivots to MI detection, scales back arrhythmia sales
HeartBeam redirects majority of resources to heart attack detection. Company estimates MI opportunity at $15 billion within $40 billion platform. Will not build large commercial team for current arrhythmia product. Seeks strategic partner for 12-lead patch with $2 billion market estimate. Submitted FDA pre-submission request for future pivotal MI study in August.
1mo agoHeartBeam enters agreement to sell up to $25M in stock via ATM
HeartBeam, Inc. announced an agreement with Titan Partners Securities to sell up to $25 million in common stock via an at-the-market offering. Filed under Form S-3 (Reg. No. 333-293307), the deal allows sales through Nasdaq Capital Market transactions or block trades. Titan Partners earns a 3% commission on gross sales.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in HeartBeam is now worth
$ 8.72
Resulting in a loss of
$ 91.28 (91.28%)
Note: Past profits do not guarantee future returns.
